X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
1. 1 Alpha-hydroxyergocalciferol
2. 1alpha(oh)2d2
3. 1alpha-hydroxyvitamin D2
4. 1alpha-ohd2
5. Doxacalciferol
6. Hectorol
1. 54573-75-0
2. Hectorol
3. 1-hydroxyergocalciferol
4. 1alpha-hydroxyergocalciferol
5. Tsa 840
6. 1alpha-hydroxyvitamin D2
7. 1-alpha-hydroxyvitamin D2
8. 1-alpha-hydroxyergocalciferol
9. 1-hydroxyvitamin D2
10. 1.alpha.-hydroxyvitamin D2
11. 1alpha-oh-d2
12. (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-1-[(e,2r,5r)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
13. 3diz9lf5y9
14. (1s,3r,5z,7e,22e)-9,10-secoergosta-5,7,10,22-tetraene-1,3-diol
15. 1.alpha.-hydroxyergocalciferol
16. Chebi:4712
17. 1-.alpha.-hydroxyergocalciferol
18. Tsa-840
19. Gz427397
20. Doxercalciferol [inn]
21. 1alpha-hydroxyvitamin D2 / 1alpha-hydroxyergocalciferol
22. (5z,7e,22e)-(1s,3r)-9,10-seco-5,7,10(19),22-ergostatetraene-1,3-diol
23. Hectorol (tn)
24. (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(e,1r,4r)-1,4,5-trimethylhex-2-enyl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylene-cyclohexane-1,3-diol
25. Vitamin D2, 1alpha-hydroxy-
26. Unii-3diz9lf5y9
27. Brn 4716774
28. Doxercalciferol [usan:inn]
29. Doxercalciferolum
30. Ncgc00182058-03
31. 1alphaohd2
32. Mfcd00871065
33. 1a-hydroxyvitamin D2
34. 1alpha-hydroxy Vitamin D2
35. (5z,7e,22e)-9,10-secoergosta-5,7,10(19),22-tetraene-1alpha,3beta-diol
36. Vitamin D2, 1a-hydroxy-
37. 1-alpha-hydroxy-vitamin D2
38. Doxercalciferol [mi]
39. Dsstox_cid_14214
40. Dsstox_rid_79125
41. Doxercalciferol (usan/inn)
42. Dsstox_gsid_34214
43. Doxercalciferol [usan]
44. Schembl322422
45. Doxercalciferol [vandf]
46. Gtpl2790
47. Doxercalciferol [mart.]
48. 1-alpha-hydroxyvitamind2
49. Chembl1200810
50. Doxercalciferol [usp-rs]
51. Doxercalciferol [who-dd]
52. Dtxsid1034214
53. Act06836
54. Ex-a4428
55. Zinc4641374
56. Tox21_112978
57. Doxercalciferol [orange Book]
58. Hsci1_000341
59. Lmst03010028
60. Akos005146517
61. Cs-0395
62. Db06410
63. Doxercalciferol [usp Monograph]
64. 9,10-secoergosta-5,7,10(19),22-tetraene-1,3-diol, (1-alpha,3-beta,5z,7e,22e)-
65. 9,10-secoergosta-5,7,10(19),22-tetraene-1,3-diol, (1.alpha.,3.beta.,5z,7e,22e)-
66. Bs-17040
67. Hy-32348
68. Cas-54573-75-0
69. 1a-hydroxyergocalciferol (ercalcidol)
70. C08211
71. D01009
72. D82103
73. 573d750
74. Q5303688
75. Doxercalciferol, >=98% (hplc), Solubility: >10 Mg/ml In Dmso
76. Doxercalciferol, United States Pharmacopeia (usp) Reference Standard
77. (5z,7e,22e)-9,10-secoergosta-5,7,10(19),22-tetraene-1.alpha.,3.beta.-diol
78. 7,10(19),22-tetraene-1,3-diol,(1-alpha,3-beta,5z,7e,22e)-10-secoergosta-5
79. 9,10-secoergosta-5,7,10(19),22-tetraene-1,3-diol, (1alpha,3beta,5z,7e,22e)-
80. (1r,3s,5z)-4-methylene-5-[(2e)-2-[(1r,3as,7ar)-octahydro-7?-methyl-1-[(1r,2e)-1,4,5-trimethyl-2-hexen-1-yl]-4h-inden-4-ylidene]ethylidene]-1,3-cyclohexanediol
81. (1r,3s,z)-5-((e)-2-((1r,3as,7ar)-1-((2r,5r,e)-5,6-dimethylhept-3-en-2-yl)-7a-methyldihydro-1h-inden-4(2h,5h,6h,7h,7ah)-ylidene)ethylidene)-4-methylenecyclohexane-1,3-diol
82. (1r,3s,z)-5-((e)-2-((1r,3as,7ar)-1-((2r,5r,e)-5,6-dimethylhept-3-en-2-yl)-7a-methylhexahydro-1h-inden-4(2h)-ylidene)ethylidene)-4-methylenecyclohexane-1,3-diol
83. 1,3-cyclohexanediol, 4-methylene-5-((2e)-2-((1r,3as,7ar)-octahydro-7a-methyl-1-((1r,2e)-1,4,5-trimethyl-2-hexen-1-yl)-4h-inden-4-ylidene)ethylidene)-, (1r,3s,5z)-
| Molecular Weight | 412.6 g/mol |
|---|---|
| Molecular Formula | C28H44O2 |
| XLogP3 | 6.3 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 5 |
| Exact Mass | 412.334130642 g/mol |
| Monoisotopic Mass | 412.334130642 g/mol |
| Topological Polar Surface Area | 40.5 Ų |
| Heavy Atom Count | 30 |
| Formal Charge | 0 |
| Complexity | 712 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 7 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 3 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 4 | |
|---|---|
| Drug Name | Doxercalciferol |
| PubMed Health | Doxercalciferol |
| Drug Classes | Calcium Regulator, Endocrine-Metabolic Agent, Nutriceutical, Nutritive Agent |
| Drug Label | Doxercalciferol is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1,25-dihydroxyvitamin D2 (1,25-(OH)2D2), a naturally occurring, biologically active form of vitamin D2. Doxercalciferol injection is supplied in... |
| Active Ingredient | Doxercalciferol |
| Dosage Form | Injectable; Capsule |
| Route | injection; Injection; Oral |
| Strength | 0.5mcg; 4mcg/2ml (2mcg/ml); 2mcg/ml; 1mcg; 2.5mcg |
| Market Status | Tentative Approval; Prescription |
| Company | Cobrek Pharma; Sandoz; Hikma Pharms; Roxane |
| 2 of 4 | |
|---|---|
| Drug Name | Hectorol |
| PubMed Health | Doxercalciferol |
| Drug Classes | Calcium Regulator, Endocrine-Metabolic Agent, Nutriceutical, Nutritive Agent |
| Drug Label | Doxercalciferol, the active ingredient in Hectorol, is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1,25-dihydroxyvitamin D2 (1,25-(OH)2D2), a naturally occurring, biologically active form of vitamin D2. H... |
| Active Ingredient | Doxercalciferol |
| Dosage Form | Capsule; Injectable |
| Route | Injection; Oral |
| Strength | 0.5mcg; 1mcg; 2mcg/ml (2mcg/ml); 4mcg/2ml (2mcg/ml); 2.5mcg |
| Market Status | Prescription |
| Company | Genzyme |
| 3 of 4 | |
|---|---|
| Drug Name | Doxercalciferol |
| PubMed Health | Doxercalciferol |
| Drug Classes | Calcium Regulator, Endocrine-Metabolic Agent, Nutriceutical, Nutritive Agent |
| Drug Label | Doxercalciferol is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1,25-dihydroxyvitamin D2 (1,25-(OH)2D2), a naturally occurring, biologically active form of vitamin D2. Doxercalciferol injection is supplied in... |
| Active Ingredient | Doxercalciferol |
| Dosage Form | Injectable; Capsule |
| Route | injection; Injection; Oral |
| Strength | 0.5mcg; 4mcg/2ml (2mcg/ml); 2mcg/ml; 1mcg; 2.5mcg |
| Market Status | Tentative Approval; Prescription |
| Company | Cobrek Pharma; Sandoz; Hikma Pharms; Roxane |
| 4 of 4 | |
|---|---|
| Drug Name | Hectorol |
| PubMed Health | Doxercalciferol |
| Drug Classes | Calcium Regulator, Endocrine-Metabolic Agent, Nutriceutical, Nutritive Agent |
| Drug Label | Doxercalciferol, the active ingredient in Hectorol, is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1,25-dihydroxyvitamin D2 (1,25-(OH)2D2), a naturally occurring, biologically active form of vitamin D2. H... |
| Active Ingredient | Doxercalciferol |
| Dosage Form | Capsule; Injectable |
| Route | Injection; Oral |
| Strength | 0.5mcg; 1mcg; 2mcg/ml (2mcg/ml); 4mcg/2ml (2mcg/ml); 2.5mcg |
| Market Status | Prescription |
| Company | Genzyme |
Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as for the treatment of secondary hyperparathyroidism in patients with Stage 3 or Stage 4 chronic kidney disease.
FDA Label
Bone Density Conservation Agents
Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS. (See all compounds classified as Bone Density Conservation Agents.)
Vitamins
Organic substances that are required in small amounts for maintenance and growth, but which cannot be manufactured by the human body. (See all compounds classified as Vitamins.)
H - Systemic hormonal preparations, excl. sex hormones and insulins
H05 - Calcium homeostasis
H05B - Anti-parathyroid agents
H05BX - Other anti-parathyroid agents
H05BX03 - Doxercalciferol
Doxercalciferol is absorbed from the gastrointestinal tract and activated by CYP 27 in the liver to form 1,25-(OH)2D2 (major metabolite) and 1,24-dihydroxyvitamin D2 (minor metabolite). Activation of doxercalciferol does not require the involvement of the kidneys.
32 to 37 hours.
Calcitriol (1,25-(OH)2D3) and 1,25-(OH)2D2 regulate blood calcium at levels required for essential body functions. Specifically, the biologically active vitamin D metabolites control the intestinal absorption of dietary calcium, the tubular reabsorption of calcium by the kidney and, in conjunction with parathyroid hormone (PTH), the mobilization of calcium from the skeleton. They act directly on bone cells (osteoblasts) to stimulate skeletal growth, and on the parathyroid glands to suppress PTH (parathyroid hormone) synthesis and secretion. These functions are mediated by the interaction of these biologically active metabolites with specific receptor proteins in the various target tissues. In patients with chronic kidney disease (CKD), deficient production of biologically active vitamin D metabolites (due to lack of or insufficient 25-hydroxyvitamin D-1-alpha-hydroxylase activity) leads to secondary hyperparathyroidism, which contributes to the development of metabolic bone disease.
Market Place
